ClinicalTrials.gg
CompletedNCT05029622Updated Feb 19, 2025Results posted

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

A Phase 3 interventional study of Triptorelin Pamoate in Central Precocious Puberty, sponsored by Ipsen. Completed at 14 sites in China. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
Up to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Puberty, Precocious with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Puberty, Precocious · China.

Enrollment
11th of 13
66 · median 94
Started
2021
with 1 other
Phase 3
4 of 17
1 open now
Registered
9th of 17
by date
Lead sponsor
2 of 17
Ipsen

Among the 17 studies in Puberty, Precocious with a site in China, this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 9th registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

4 of the 17 studies in Puberty, Precocious with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: Up to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Puberty, Precocious with a site in China, or all of them as a file.
02

Study summary

The purpose of the protocol is to assess the efficacy of the triptorelin 6 month PR (Prolonged Release) formulation in suppressing LH (Luteinising hormone) levels to prepubertal levels (defined as a peak LH ≤5 IU/L) after i.v. GnRH (Gonadotropin-releasing Hormone) stimulation at Month 6 (Day 169) in Chinese children with CPP (Central Precocious Puberty).

03

Conditions studied

  • Central Precocious Puberty

Browse trials for

04

Who can participate

Ages eligible
Up to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is less than 9 years old for girls and less than 10 years old for boys at initiation of triptorelin treatment or at the time of signing the .
  • Participant must present evidence of CPP documented by:
  • Onset of development of secondary sex characteristics (breast development in girls or testicular enlargement in boys according to the Tanner method: Stage II) before the age of 8 years in girls and 9 years in boys.
  • Pubertal response of LH to GnRH stimulation test (stimulated peak LH ≥6 IU/L) in both sexes.
  • Difference between bone age (BA) and CA >1 year.
  • Girls with Tanner staging ≥2 for breast development and who have enlarged uterine length and/or ovarian volume and at last 2 follicles with diameter >4 mm in the ovary observed by pelvic type B ultrasound at the Screening visit; boys who have testicular volume ≥4 mL observed by testicular orchidometer at the Screening visit.
  • Girls who have already had menophania/menarche must have a negative highly sensitive (urine) pregnancy test as required by local regulations within 24 hours before the first dose of study intervention and should not be at risk of pregnancy throughout the study period.

Exclusion criteria

Exclusion Criteria:

  • Gonadotropin-independent (peripheral) precocious puberty: extrapituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex secretion.
  • Non-progressing isolated premature thelarche.
  • Presence of an unstable intracranial tumour or an intracranial tumour requiring neurosurgery or cerebral irradiation. Participants with hamartomas not requiring surgery are eligible.
  • Prior or current therapy with a GnRHa (Gonadotropin-releasing Hormone Agonist) , medroxyprogesterone acetate, growth hormone or insulin-like growth factor 1 (IGF 1).Use of anticoagulants (heparin and coumarin derivatives) within the 2 weeks prior to the Screening visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Triptorelin formulation for Intramuscular injection (IM).

    Drug: Triptorelin Pamoate

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Luteinising Hormone (LH) Suppression

    LH response was defined as a peak LH \<=5 international units per liter (IU/L) after intravenous (IV) gonadotropin-releasing hormone (GnRH) stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

    Time frame: At Month 6

Secondary outcomes

  1. Percentage of Participants With LH Response to GnRH Test

    LH response was defined as a peak LH \<=5 IU/L after IV GnRH stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

    Time frame: At Months 3 and 12

  2. Change From Baseline in Basal Serum LH and Follicle-Stimulating Hormone (FSH) Levels

    Basal LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the values for LH and FSH at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

    Time frame: Baseline and at Months 3, 6, 9 and 12

  3. Change From Baseline in Peak Serum LH and FSH Level After the GnRH Stimulation Test

    Peak LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the values for LH and FSH at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) after a single IV injection of gonadorelin. A suppressed LH response to GnRH stimulation test was defined as peak serum LH \<=5 IU/L among the four timepoints (T0, T30, T60 and T90). The FSH response to GnRH stimulation was the peak serum FSH level among the four timepoints (T0, T30, T60 and T90).

    Time frame: Baseline and at Months 3, 6 and 12

  4. Percentage of Participants With LH Response (Peak LH <=5 IU/L) From Month 6 to Month 12

    Peak LH serum concentration was analyzed centrally. LH response was defined as a peak LH \<=5 IU/L after IV GnRH stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of peak LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

    Time frame: Month 6 to Month 12

  5. Percentage of Participants With Prepubertal Levels of Sex Steroids

    Prepubertal sex steroids assessment included estradiol in female participants and testosterone in male participants. Prepubertal sex steroids levels were defined as: estradiol \<=20 picogram (pg)/ milliliter (mL) in female participants and testosterone \<=30 nanogram (ng)/ deciliter (dL) in male participants. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

    Time frame: At Months 3, 6, 9 and 12

  6. Change From Baseline in Mean Height for Age (Z-Score)

    Z-scores are calculated using Centers for Disease Control and Prevention (CDC) Growth Charts. Change from baseline was defined as the values for Z-score at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to study treatment administration. Negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.

    Time frame: Baseline and at Months 6 and 12

  7. Change From Baseline in Percentile for Height for Age

    Z-scores were calculated using CDC growth charts, that contained Box-Cox transformation (L), the median (M) and the generalized coefficient of variation (S). Percentile was obtained using the following equation M (1 + LSZ) \*\* (1/L), where \*\* indicated an exponent, such that m (1+LSZ)\*\* (1/L) meant raising (1+LSZ) to the (1/L)th power and then multiplying the M. Z was the Z-score that corresponds to the percentile. Negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline was defined as the values for percentile of Z-score at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

    Time frame: Baseline and at Months 6 and 12

  8. Change From Baseline in Growth Velocity

    Growth velocity analysis was part of auxological parameter. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

    Time frame: Baseline and at Months 6 and 12

  9. Percentage of Participants With Bone Age (BA)/Chronological Age (CA) Ratio Not Risen

    BA was determined using X-rays of the hand and wrist by Greulich and Pyle method. CA was calculated as (visit date -birth date + 1)/365.25. Percentage of response was calculated as n/N\*100, where n was number of participants in the specified category and N was number of participants in the analysis population.

    Time frame: At Months 6 and 12

  10. Change From Baseline in BA:CA Ratio

    BA was determined using X-rays of the hand and wrist by Greulich and Pyle method. CA was calculated as (visit date -birth date + 1)/365.25. Change from baseline was defined as the values for BA:CA ratio at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

    Time frame: Baseline, Months 6 and 12

  11. Percentage of Participants With Stabilized Pubertal Stage

    Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital development stage (GDS) in male participants, breast development stage (BDS) in female participants and pubic hair development (PHD) stage in both sexes. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

    Time frame: At Months 6 and 12

  12. Percentage of Participants With Regression of Uterine Length

    Uterine length was determined by transabdominal ultrasound. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

    Time frame: At Months 6 and 12

  13. Percentage of Participants With Absence of Progression of Testis Volumes

    Testis volume was a clinical assessment with orchidometer. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

    Time frame: At Months 6 and 12

  14. Change From Baseline in Body Mass Index (BMI)

    BMI analysis was part of auxological parameter assessment. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

    Time frame: Baseline and at Months 6 and 12

  15. Change From Baseline in Weight

    Weight analysis was part of auxological parameter assessment. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

    Time frame: Baseline and at Months 6 and 12

  16. Plasma Concentrations of Triptorelin

    Blood samples were collected at specified timepoints.

    Time frame: Day 1, 4 hours post-injection; Month 3; Month 6, predose; Month 6, 4 hours post-injection; and Month 12

07

Results

Posted May 28, 2024

Participant flow

This Phase 3, open-label, single arm, study was conducted in children with central precocious puberty (CPP) at 12 investigational sites in China from 25 August 2021 to 13 February 2023.

Participant flow — Overall Study
MilestoneAll Participants
Started66
Completed65
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Participants With Luteinising Hormone (LH) Suppression

LH response was defined as a peak LH \<=5 international units per liter (IU/L) after intravenous (IV) gonadotropin-releasing hormone (GnRH) stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

Time frame:
At Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With Luteinising Hormone (LH) Suppression
percentage of participantsAll Participants
Percentage of Participants With Luteinising Hormone (LH) Suppression100 (94.6 to 100.0)
SecondaryPercentage of Participants With LH Response to GnRH Test

LH response was defined as a peak LH \<=5 IU/L after IV GnRH stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

Time frame:
At Months 3 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With LH Response to GnRH Test
percentage of participantsAll Participants
Month 397.0 (89.5 to 99.6)
Month 1298.5 (91.8 to 100.0)
SecondaryChange From Baseline in Basal Serum LH and Follicle-Stimulating Hormone (FSH) Levels

Basal LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the values for LH and FSH at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

Time frame:
Baseline and at Months 3, 6, 9 and 12
Reported as:
Mean · IU/L
Change From Baseline in Basal Serum LH and Follicle-Stimulating Hormone (FSH) Levels
IU/LAll Participants
LH, Month 3-1.6420 ± 2.4287
LH, Month 6-1.8015 ± 2.4109
LH, Month 9-1.6307 ± 2.3396
LH, Month 12-1.8504 ± 2.4524
FSH, Month 3-2.9938 ± 1.9450
FSH, Month 6-2.4871 ± 2.0414
FSH, Month 9-2.8586 ± 1.9310
FSH, Month 12-2.5348 ± 1.9162
SecondaryChange From Baseline in Peak Serum LH and FSH Level After the GnRH Stimulation Test

Peak LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the values for LH and FSH at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) after a single IV injection of gonadorelin. A suppressed LH response to GnRH stimulation test was defined as peak serum LH \<=5 IU/L among the four timepoints (T0, T30, T60 and T90). The FSH response to GnRH stimulation was the peak serum FSH level among the four timepoints (T0, T30, T60 and T90).

Time frame:
Baseline and at Months 3, 6 and 12
Reported as:
Mean · IU/L
Change From Baseline in Peak Serum LH and FSH Level After the GnRH Stimulation Test
IU/LAll Participants
LH, Month 3-26.0075 ± 19.8863
LH, Month 6-26.2867 ± 20.3004
LH, Month 12-26.6065 ± 20.5680
FSH, Month 3-11.7297 ± 5.1787
FSH, Month 6-10.0656 ± 5.0160
FSH, Month 12-10.1645 ± 5.2442
SecondaryPercentage of Participants With LH Response (Peak LH <=5 IU/L) From Month 6 to Month 12

Peak LH serum concentration was analyzed centrally. LH response was defined as a peak LH \<=5 IU/L after IV GnRH stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of peak LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

Time frame:
Month 6 to Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With LH Response (Peak LH <=5 IU/L) From Month 6 to Month 12
percentage of participantsAll Participants
Percentage of Participants With LH Response (Peak LH <=5 IU/L) From Month 6 to Month 1298.5 (91.8 to 100.0)
SecondaryPercentage of Participants With Prepubertal Levels of Sex Steroids

Prepubertal sex steroids assessment included estradiol in female participants and testosterone in male participants. Prepubertal sex steroids levels were defined as: estradiol \<=20 picogram (pg)/ milliliter (mL) in female participants and testosterone \<=30 nanogram (ng)/ deciliter (dL) in male participants. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

Time frame:
At Months 3, 6, 9 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Prepubertal Levels of Sex Steroids
percentage of participantsAll Participants
Month 397.0 (89.5 to 99.6)
Month 6100 (94.6 to 100.0)
Month 986.4 (75.7 to 93.6)
Month 1298.5 (91.8 to 100.0)
SecondaryChange From Baseline in Mean Height for Age (Z-Score)

Z-scores are calculated using Centers for Disease Control and Prevention (CDC) Growth Charts. Change from baseline was defined as the values for Z-score at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to study treatment administration. Negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.

Time frame:
Baseline and at Months 6 and 12
Reported as:
Mean · Z-score
Change From Baseline in Mean Height for Age (Z-Score)
Z-scoreAll Participants
Month 60.0734 ± 0.1433
Month 120.0204 ± 0.1567
SecondaryChange From Baseline in Percentile for Height for Age

Z-scores were calculated using CDC growth charts, that contained Box-Cox transformation (L), the median (M) and the generalized coefficient of variation (S). Percentile was obtained using the following equation M (1 + LSZ) \*\* (1/L), where \*\* indicated an exponent, such that m (1+LSZ)\*\* (1/L) meant raising (1+LSZ) to the (1/L)th power and then multiplying the M. Z was the Z-score that corresponds to the percentile. Negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline was defined as the values for percentile of Z-score at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

Time frame:
Baseline and at Months 6 and 12
Reported as:
Mean · percentiles of Z-score
Change From Baseline in Percentile for Height for Age
percentiles of Z-scoreAll Participants
Month 61.4675 ± 2.8638
Month 120.2810 ± 3.2237
SecondaryChange From Baseline in Growth Velocity

Growth velocity analysis was part of auxological parameter. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

Time frame:
Baseline and at Months 6 and 12
Reported as:
Mean · centimeter (cm)/year
Change From Baseline in Growth Velocity
centimeter (cm)/yearAll Participants
Month 6-3.938 ± 6.075
Month 12-4.798 ± 5.577
SecondaryPercentage of Participants With Bone Age (BA)/Chronological Age (CA) Ratio Not Risen

BA was determined using X-rays of the hand and wrist by Greulich and Pyle method. CA was calculated as (visit date -birth date + 1)/365.25. Percentage of response was calculated as n/N\*100, where n was number of participants in the specified category and N was number of participants in the analysis population.

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Bone Age (BA)/Chronological Age (CA) Ratio Not Risen
percentage of participantsAll Participants
Month 695.5 (87.3 to 99.1)
Month 1292.4 (83.2 to 97.5)
SecondaryChange From Baseline in BA:CA Ratio

BA was determined using X-rays of the hand and wrist by Greulich and Pyle method. CA was calculated as (visit date -birth date + 1)/365.25. Change from baseline was defined as the values for BA:CA ratio at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

Time frame:
Baseline, Months 6 and 12
Reported as:
Mean · ratio
Change From Baseline in BA:CA Ratio
ratioAll Participants
Month 6-0.04 ± 0.06
Month 12-0.06 ± 0.07
SecondaryPercentage of Participants With Stabilized Pubertal Stage

Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital development stage (GDS) in male participants, breast development stage (BDS) in female participants and pubic hair development (PHD) stage in both sexes. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Stabilized Pubertal Stage
percentage of participantsAll Participants
BDS for female participants, Month 698.4 (91.3 to 100.0)
GDS for male participants, Month 6100 (39.8 to 100.0)
PHD for female participants, Month 691.9 (82.2 to 97.3)
PHD for male participants, Month 6100 (39.8 to 100.0)
BDS for female participants, Month 1293.5 (84.3 to 98.2)
GDS for male participants, Month 12100 (39.8 to 100.0)
PHD for female participants, Month 1287.1 (76.1 to 94.3)
PHD for male participants, Month 1275.0 (19.4 to 99.4)
SecondaryPercentage of Participants With Regression of Uterine Length

Uterine length was determined by transabdominal ultrasound. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Regression of Uterine Length
percentage of participantsAll Participants
Month 664.5 (51.3 to 76.3)
Month 1264.5 (51.3 to 76.3)
SecondaryPercentage of Participants With Absence of Progression of Testis Volumes

Testis volume was a clinical assessment with orchidometer. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Progression of Testis Volumes
percentage of participantsAll Participants
Month 675.0 (19.4 to 99.4)
Month 1275.0 (19.4 to 99.4)
SecondaryChange From Baseline in Body Mass Index (BMI)

BMI analysis was part of auxological parameter assessment. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

Time frame:
Baseline and at Months 6 and 12
Reported as:
Mean · kilogram (kg)/meter square
Change From Baseline in Body Mass Index (BMI)
kilogram (kg)/meter squareAll Participants
Month 60.282 ± 0.882
Month 121.195 ± 1.196
SecondaryChange From Baseline in Weight

Weight analysis was part of auxological parameter assessment. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.

Time frame:
Baseline and at Months 6 and 12
Reported as:
Mean · kg
Change From Baseline in Weight
kgAll Participants
Month 62.020 ± 1.927
Month 125.146 ± 2.816
SecondaryPlasma Concentrations of Triptorelin

Blood samples were collected at specified timepoints.

Time frame:
Day 1, 4 hours post-injection; Month 3; Month 6, predose; Month 6, 4 hours post-injection; and Month 12
Reported as:
Geometric mean · ng/mL
Plasma Concentrations of Triptorelin
ng/mLAll Participants
Day 1, 4 hours post-injection41.8 ± 56.9
Month 30.0434 ± 76.8
Month 6, predose0.0251 ± 648.7
Month 6, 4 hours post-injection24.7 ± 66.0
Month 120.0223 ± 110.3

Adverse events

Collected over Treatment-emergent adverse events were reported from the first dose of study treatment (Day 1) up to a maximum of approximately 344 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants0/66 (0%)0/66 (0%)59/66 (89.4%)
Most frequent other events
Showing 10 of 59
Most frequent other events
EventAll Participants
Upper respiratory tract infectionInfections and infestations31/66
COVID-19Infections and infestations10/66
PyrexiaGeneral disorders9/66
Weight increasedInvestigations9/66
CoughRespiratory, thoracic and mediastinal disorders7/66
OverweightMetabolism and nutrition disorders7/66
Suspected COVID-19Infections and infestations4/66
BronchitisInfections and infestations4/66
Rhinitis allergicRespiratory, thoracic and mediastinal disorders3/66
Abdominal painGastrointestinal disorders3/66

Baseline characteristics

The intention-to-treat (ITT) population consisted of all participants who received at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(years)All Participants
Mean7.5 ± 0.9
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female62
Male4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Chinese66
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino66
08

Study locations

14 sites
  • Beijing Children's Hospital, Capital Medical University
    Beijing, 100045, China
  • No.1 Hospital of Jilin University (Bethune first hospital of Jilin University)
    Changchun, 130021, China
  • Children's Hospital of Fudan University
    Changhai, 201102, China
  • Hunan children's hospital
    Changsha, 410007, China
  • Chengdu Women's & Children's Central Hospital
    Chengdu, 610073, China
  • Shandong Provincial Hospital
    Jinan, 250021, China
  • Linyi Maternal and Child Health Care Hospital
    Linyi, 276016, China
  • Jiangxi Provincial Children's Hospital
    Nanchang, 330006, China
  • Pingxiang Maternity and Child Care
    Pingxiang, 337000, China
  • Children's Hospital of Soochow University
    Suzhou, 215031, China
  • Wuhan Children's Hospital Tongji Medical College Huazhong University of Science & Technology
    Wuhan, 430015, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Wuhan, 430030, China
  • Wuxi children's Hospital
    Wuxi, 214023, China
  • Zhengzhou Children's Hospital , Henan Children's Hospital
    Zhengzhou, 450018, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.

Access criteria: Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Aug 2022, 12 months.

Results were first posted in May 2024, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2021
First posted
Aug 31, 2021
StartActual
Aug 10, 2021
Primary completionActual
Aug 21, 2022
CompletionActual
Feb 13, 2023
Results first posted
May 28, 2024
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05029622
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Aug 10, 2021
Primary completion
Aug 21, 2022
Completion
Feb 13, 2023
Results posted
May 28, 2024
Last update
Feb 19, 2025

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion